Compounding US FDA’s Problems: The High Stakes In GLP-1 Shortage Actions

The explosion in pharmacy compounding as a source of GLP-1 weight loss medications has put the FDA in a tough spot to defend its drug shortage policies, but it is not the first time that compounding has posed a potentially significant threat to agency authorities.

The FDA is facing a court challenge of its decision to end the shortage of brand GLP-1s. (Shutterstock)

More from Manufacturing

More from Compliance